Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis

Inclusion Criteria: * Diagnosed with chronic kidney disease receiving hemodialysis 3 times a week for at least 3 months prior to obtaining the informed consent and scheduled to be receiving the same hemodialysis during the study period. * Using dialysate with constant concentration of calcium for 4 weeks prior to obtaining informed consent and phosphate binder with constant dose regimen for 2 weeks prior to obtaining informed consent. * Intact parathyroid hormone level (iPTH) ≥ 300 pg/mL * Calcium (adjusted) 8.4-10.2 milligrams/deciliter (mg/dL) * Phosphorus ≤ 6.5 mg/dL * Age ≥ 20 years Exclusion Criteria: * History of allergic reaction or significant sensitivity to vitamin D or vitamin D related compounds * Parathyroidectomy or ethanol infusion within past year * Progressive malignancy or clinically significant hepatic diseases, severe cerebral/cardiovascular diseases, severe hypertension, or uncontrolled diabetes mellitus * Drug or alcohol abuse within past 6 months * Taking calcitonin, maintenance intravenous or oral glucocorticoids, cinacalcet, bisphosphonates, selective estrogen-receptor modulator (SERM), vitamin D compounds (other than study drug), or other drugs that may affect calcium or bone metabolism (other than estrogen or progestin, vitamin K2) * Will need to take chronic dose (≥ 2 consecutive weeks) of cytochrome P450 (CYP3A) inhibitors (e.g., clarithromycin, grapefruit products) or inducers (e.g., carbamazepine, rifampicin) * Taking aluminum containing produ…